Neurotech International (NTI) Price & Analysis

Compare

11 Followers

NTI Stock Chart & Stats

AU$0.02

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.02

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.01 - AU$0.04

Previous CloseN/A

Volume11.09K

Average Volume (3M)768.84K

Market Cap

AU$16.85M

Enterprise ValueAU$11.11M

Total Cash (Recent Filing)AU$3.03M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta0.44

Next Earnings

Mar 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding1,296,313,100

10 Day Avg. Volume770,041

30 Day Avg. Volume768,844

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)5.26

Price to Sales (P/S)6.36

P/FCF Ratio-1.72

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.01

Revenue Forecast (FY)AU$6.58M

Bulls Say, Bears Say

Bulls Say

Minimal Leverage / Low Solvency RiskZero reported debt gives the company structural flexibility: lower fixed financing costs and reduced solvency risk improve its ability to pursue R&D or clinical milestones without immediate interest burden. This durable capital structure reduces bankruptcy risk and eases future financing timing decisions.

Recent Revenue ReboundA material revenue rebound from near-zero to ~A$2.44m shows the business can start converting R&D/clinical activities into commercial receipts. While still small, sustained growth from this base would indicate improving product adoption or licensing traction, supporting longer-term scaling prospects if continued.

Focused R&D On Neurological DisordersA clear strategic focus on neurological and neurodevelopmental indications and cannabinoid-based compounds creates a concentrated pipeline and expertise. This specialization can lead to durable competitive advantages via IP, clinical know-how and targeted partnerships in a high-unmet-need therapeutic area.

Bears Say

Accelerating Cash BurnFree cash flow deterioration to roughly -A$9.0m shows the company is burning cash faster as activity ramps. This persistent negative cash generation is structurally important: it forces repeated external funding, increases dilution risk, and constrains ability to fund clinical development organically without capital markets access.

Persistent Operating LossesOperating losses that far exceed revenues indicate the cost base and development spending materially outstrip commercial returns. Until the company establishes sustained profitable margins or substantially larger revenue scale, the business model remains structurally loss-making and reliant on external capital to continue operations.

Eroding Equity Base And Funding RelianceMaterial decline in equity reflects cumulative losses and/or dilution, weakening the balance sheet buffer. A smaller equity base reduces financial flexibility, raises the likelihood of future capital raises, and increases potential shareholder dilution, which are enduring risks until profitability or cash self-sufficiency is achieved.

Neurotech International News

Neurotech’s NTI164 Shows Strong Long-Term Safety in Key Toxicology Study

Neurotech International ( ($AU:NTI) ) just unveiled an update. Neurotech International has reported that its lead oral cannabinoid...

21h ago

NTI

Neurotech International Calls March General Meeting, Moves to Digital Meeting Notices

Neurotech International ( ($AU:NTI) ) has issued an announcement. Neurotech International has called a general meeting of shareholders...

14d ago

NTI

Neurotech Wins Ethics Approval for Pivotal Phase 3 Autism Trial of NTI164

The latest announcement is out from Neurotech International ( ($AU:NTI) ). Neurotech International has secured Human Research Ethics...

22d ago

NTI

Neurotech Advances Lead Paediatric Neurology Drug NTI164 with New FDA Designation, Data and Funding

The latest announcement is out from Neurotech International ( ($AU:NTI) ). Neurotech International reported a pivotal quarter marked...

25d ago

NTI

Neurotech’s NTI164 PANS Data Published in Leading Journal, Bolstering Paediatric Neuro Portfolio

Neurotech International ( ($AU:NTI) ) has provided an update. Neurotech International has reported that clinical and mechanistic data...

1M ago

NTI

Neurotech Issues New Shares, Affirms Regulatory Compliance

Neurotech International ( ($AU:NTI) ) has issued an update. Neurotech International has issued new ordinary fully paid shares...

2M ago

NTI

Neurotech Seeks ASX Quotation for 246.7 Million New Shares

An announcement from Neurotech International ( ($AU:NTI) ) is now available. Neurotech International has applied to the ASX...

2M ago

NTI

Neurotech Director’s 5 Million Options Lapse, Reducing Potential Equity Exposure

Neurotech International ( ($AU:NTI) ) has provided an update. Neurotech International has disclosed a change in director Gerald...

2M ago

NTI

Neurotech Options Lapse, Streamlining Capital Structure

Neurotech International ( ($AU:NTI) ) has provided an update. Neurotech International Limited has allowed 5 million unlisted options,...

2M ago

NTI

Neurotech International Secures $4 Million to Advance Paediatric Neurological Treatments

Neurotech International ( ($AU:NTI) ) has shared an announcement. Neurotech International has secured binding commitments for a $4...

2M ago

NTI

NTI FAQ

What was Neurotech International Ltd.’s price range in the past 12 months?

Neurotech International Ltd. lowest share price was AU$0.01 and its highest was AU$0.04 in the past 12 months.

What is Neurotech International Ltd.’s market cap?

Neurotech International Ltd.’s market cap is AU$16.85M.

When is Neurotech International Ltd.’s upcoming earnings report date?

Neurotech International Ltd.’s upcoming earnings report date is Mar 03, 2026 which is in 8 days.

How were Neurotech International Ltd.’s earnings last quarter?

Neurotech International Ltd. released its earnings results on Aug 29, 2025. The company reported -AU$0.003 earnings per share for the quarter, beating the consensus estimate of -AU$0.005 by AU$0.002.

Is Neurotech International Ltd. overvalued?

According to Wall Street analysts Neurotech International Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Neurotech International Ltd. pay dividends?

Neurotech International Ltd. does not currently pay dividends.

What is Neurotech International Ltd.’s EPS estimate?

Neurotech International Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Neurotech International Ltd. have?

Neurotech International Ltd. has 1,296,313,100 shares outstanding.

What happened to Neurotech International Ltd.’s price movement after its last earnings report?

Neurotech International Ltd. reported an EPS of -AU$0.003 in its last earnings report, beating expectations of -AU$0.005. Following the earnings report the stock price went up 7.692%.

Which hedge fund is a major shareholder of Neurotech International Ltd.?

Currently, no hedge funds are holding shares in AU:NTI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Neurotech International Stock Smart Score

Underperform

Fundamentals

Return on Equity

-142.71%

Trailing 12-Months

Asset Growth

-73.47%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Neurotech International Ltd.

Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on development and commercializing Mente platform, a platform technology to monitor and play role in home-based therapies. Its product includes Mente Autism for the diagnosis and treatment of autism. It also engages in executing of medical research projects; and developing of technological devices. The company was incorporated in 2016 and is based in Nedlands, Australia.